Our data showing a lag of 2–4 days for induction of circulating HMGB1 in response to influenza (41), coupled with the partial efficacy of Eritoran as late as 6 days p.i. (14), suggests there is a therapeutic window in influenza-induced ALI. Here, HMGB1 is linked to influenza.